ABSTRACT
Objective@#To compare the effects of Jinghua Weikang capsule and bismuth potassium citrate in the treatment of Helicobacter pylori(Hp) infection.@*Methods@#From July 2016 to April 2018, 124 patients who were diagnosed as Hp positive by gastrointestinal urease test and 13C breath test at the First Affiliated Hospital of He'nan University were randomly divided into group A(63 cases) and group B(61 cases) according to the digital table.Group A received bismuth potassium citrate + standard triple therapy, treatment for 14 days.Group B was given Jinghua Weikang capsule+ standard triple therapy, treatment for 14 days.One month after treatment, the treatment effect of the two regimens was recorded.@*Results@#The total effective rates of group A and group B after one course of treatment were 88.89%(56/63) and 93.44%(57/61), respectively, the difference was no statistically significant between the two groups(χ2=0.795, P=0.373). The Hp eradication rates of group A and group B were 84.13%(53/63) and 95.08%(58/61), respectively, the difference was statistically significant(χ2=3.963, P=0.047). The proportions of patients with improved symptoms within 7 days in group A and group B were 68.25%(43/63) and 83.61%(51/61), respectively, the difference was statistically significant(χ2=3.983, P=0.046). The incidences of adverse reactions in group A and group B were 14.29%(9/63) and 3.28%(2/61), respectively, the difference was statistically significant(χ2=4.645, P=0.031).@*Conclusion@#Compared with bismuth potassium citrate, Jinghua Weikang capsule has similar clinical effect after one course of treatment, higher Hp eradication rate, lower incidence of adverse reactions, faster symptom improvement, and the satisfaction and compliance of patients are higher.
ABSTRACT
Objective To compare the effects of Jinghua Weikang capsule and bismuth potassium citrate in the treatment of Helicobacter pylori (Hp) infection.Methods From July 2016 to April 2018,124 patients who were diagnosed as Hp positive by gastrointestinal urease test and 13C breath test at the First Affiliated Hospital of He'nan University were randomly divided into group A (63 cases) and group B (61 cases) according to the digital table. Group A received bismuth potassium citrate +standard triple therapy ,treatment for 14 days.Group B was given Jinghua Weikang capsule +standard triple therapy,treatment for 14 days.One month after treatment ,the treatment effect of the two regimens was recorded.Results The total effective rates of group A and group B after one course of treatment were 88.89%(56／63) and 93.44%(57／61),respectively,the difference was no statistically significant between the two groups(χ2 ＝0.795,P＝0.373).The Hp eradication rates of group A and group B were 84.13%(53／63) and 95.08%(58／61),respectively,the difference was statistically significant (χ2 ＝3.963,P＝0.047).The proportions of patients with improved symptoms within 7 days in group A and group B were 68.25%(43／63) and 83.61%(51／61),respectively,the difference was statistically significant (χ2 ＝3.983,P＝0.046).The incidences of adverse reactions in group A and group B were 14.29%(9／63) and 3.28%(2／61),respectively,the difference was statistically significant(χ2 ＝4.645,P ＝0.031).Conclusion Compared with bismuth potassium citrate , Jinghua Weikang capsule has similar clinical effect after one course of treatment ,higher Hp eradication rate ,lower incidence of adverse reactions,faster symptom improvement ,and the satisfaction and compliance of patients are higher.
ABSTRACT
Objective To explore the clinical eficacy of umbilical cord blood stem cell transplantation in treatment of decompensated cirrhosis.Methods Thirty patients with decompensated cirrhosis were given umbilical cord blood stem cell transplantation (treatment group) and 30 patients with decompensated cirrhosis were given traditional treatment (control group).Liver function and blood coagulation function was tested after 4,8 weeks treatment respectively,and adverse effects were recorded at the same time.Results After 8 weeks treatment,total bilirubin,albumin and prothrombin time in treatment group was improved compared with that before treatment[(71.3 ± 37.8) μ mol/L vs.(107.3 ± 53.2) μ mol/L,(30.1 ± 4.9) g/L vs.(27.5 ± 5.1) g/L,(15.0 ± 2.9) s vs.(16.7 ± 3.9) s],and there was significant difference (P ＜ 0.05).There was no significant difference in the index before and after treatment in control group (P＞ 0.05).No obvious adverse reactions were observed in the process of umbilical cord blood stem cell transplantation.Conclusion Umbilical cord blood stem cell transplantation is safe and effective in treatment of deeompensated cirrhosis.
ABSTRACT
Objective To Study The relationship between the serum markers with liver fibrosis in chronic hepatitis B and changes in liver histology. Methods The serum levels of hyaluronic acid (HA),procollagen type Ⅲ(PCⅢ),laminin(LN),typeⅣ procollagen (IV.C) and transforming growth factor ?1(TGF-?1) were measured by RIA Kit in patient with chronic hepatitis B. At the same time ,liver biopsy was performed.Results The serum levels of above five markers increased with hepatitis and fibrosis progression . The relationship between the serum levels of PC Ⅲ with hepatitis was close,both HA and TGF-?1 was closely related to fibrosis.Conclusion The combinated assay of serum levels of above five markers can identify pathological stages of hepatic fibrosis and hepatitis .
ABSTRACT
Objective To estimate the prevalence of erectile dysfunction (ED) among the patients undergoing manintenance hemodialysis (MHD), and evaluate the efficacy and the adverse effects of sildenafil for ED. Methods The international index of erectile function questionnaire (IIEF) was used to estimate 22 male MHD cases. ED patients were administered sildenafil with the initial dose of 25 mg/d, then maximum of 100 mg/d for 12 weeks. Results 72. 73% (16/22) of MHD patients complained of ED, and the total effective rate of sildenafil was 87.5% (14/16) with common adverse effects-headache and flushing. Conclusion Sildenafil in MHD patients has similar efficacy and safety as the others.